# A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease

> **NCT06973668** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 80 (estimated)

## Conditions studied

- AML

## Interventions

- **DRUG:** Mycophenolate Mofetil
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT06973668
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-22
- **Primary completion:** 2028-01-31
- **Final completion:** 2030-01-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06973668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06973668, "A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06973668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*